Resurrection of Oral Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: A Historical Account From Bedside to Bench to Bedside.

ABSTRACT: Various forms of arsenic were used in China and elsewhere for over 5,000 years. Following the initial success of intravenous arsenic trioxide (i.v. As₂O₃), we revived an oral formulation of pure As₂O₃ in 1998 for the treatment of acute promyelocytic leukemia (APL). We were the first to produce a 1 mg/ml oral-As₂O₃ solution and showed that it had comparable bioavailability to i.v. As₂O₃. Moreover, we also reported that intracellular arsenic concentrations were considerably higher than the corresponding plasma values. Our oral-As₂O₃ was patented internationally and registered in Hong Kong for the treatment of APL. Safety, tolerability and clinical efficacy was confirmed in long-term

SUBMITTER: Kumana CR 

PROVIDER: S-EPMC7418518 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature